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Abstract  
 
The tight coupling between neuronal activity and the local increase of blood flow termed neurovascular coupling 
is essential for normal brain function. This mechanism of regulation is compromised in Alzheimer’s Disease 
(AD). In order to determine whether a purely vascular dysfunction or a neuronal alteration of blood vessels 
diameter control could be responsible for the impaired neurovascular coupling observed in AD, blood vessels 
reactivity in response to different pharmacological stimulations was examined in double transgenic APPxPS1 
mice model of AD. 
Blood vessels movements were monitored using infrared videomicroscopy ex vivo, in cortical slices of 8 month-
old APPxPS1 and wild type (WT) mice. We quantified vasomotor responses induced either by direct blood 
vessel stimulation with a thromboxane A2 analogue, the U46619 (9,11-dideoxy-11a,9a-
epoxymethanoprostaglandin F2α) or via the stimulation of interneurons with the nicotinic acetylcholine receptor 
(nAChRs) agonist DMPP (1,1-Dimethyl-4-phenylpiperazinium iodide). Using both types of stimulation, no 
significant differences were detected for the amplitude of blood vessel diameter changes between the transgenic 
APPxPS1 mice model of AD and WT mice, although the kinetics of recovery were slower in APPxPS1 mice. 
We find that activation of neocortical interneurons with DMPP induced both vasodilation via Nitric Oxide (NO) 
release and constriction via Neuropeptide Y (NPY) release. However, we observed a smaller proportion of 
reactive blood vessels following a neuronal activation in transgenic mice compared with WT mice. Altogether, 
these results suggest that in this mouse model of AD, deficiency in the cortical neurovascular coupling 
essentially results from a neuronal and not a vascular dysfunction.  
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Introduction  
Alzheimer’s Disease (AD) is a multifactorial and progressive neurodegenerative pathology associated with 
various vascular dysfunctions. During AD development, levels of beta amyloid (A) peptides increase and form 
depositions in neuritic plaques and in cerebral blood vessels, causing cerebral amyloid angiopathy (CAA). 
Disturbances in neuronal circuits, such as loss of neurons and synapses [1-3] as well as progressive vascular 
dysregulation [4] are well known features of this pathology.  
Neurons and astrocytes are known to function in a close metabolic and structural interdependence with blood 
vessels forming the so called neurovascular unit [5,6]. The tight coupling between increased neuronal activity 
and local control of cerebral blood vessels diameter known as neurovascular coupling or functional hyperemia is 
precociously altered in AD patients [7-10] and in various AD transgenic mouse models [4,11-13]. In AD, 
ultrastructural changes affecting diverse properties of the neurovascular unit have been observed, such as 
capillary distortions, blood-brain-barrier (BBB) dysfunction, losses of endothelial mitochondria, thickening of 
the basement membrane, endothelial degeneration, increase in degererative pericytes, perivascular 
neuroinflammation [14]. Moreover, early in the physiopathological development of the disease, the AD brain is 
characterized by an altered perfusion to activated areas [15]. These ultrastructural changes affecting the 
neurovascular unit result in disturbed regulatory mechanisms and contribute to cerebral damage.  
This neurovascular dysfunction observed in AD could result from purely vascular alterations or from a 
neurodegenerative process [16-18] and a progressive loss of the neuronal control of blood vessels tonus.  
Using pharmacological stimulation of blood vessels within cortical slices, the objective of this study was to 
determine ex vivo, the vascular or neuronal origin of the impaired neurovascular coupling occurring during AD. 
To this aim, here we used 8 month-old double transgenic mice overexpressing human mutated genes of both 
human amyloid precursor protein (APP751 with both the Swedish and London mutations; SL) and 
humanpresenilin 1 (PS1M146L) [19]. This APPxPS1 mouse model of AD develops early-onset brain 
amyloidosis (3-4 months), undergoes substantial cell loss and CAA could first be detected from about 20 weeks 
of age. We performed direct stimulation of blood vessels using a thromboxane A2 analogue, the U46619 (9,11-
dideoxy-11a,9a-epoxymethanoprostaglandin F2α) acting on G-protein coupled thromboxane receptor located on 
endothelial cells of blood vessels [20], or indirect stimulation via neuronal activation using the nicotinic 
acetylcholine receptor (nAchRs) agonist DMPP (1,1-Dimethyl-4-phenylpiperazinium iodide). Indeed, in the 
neocortex, the neurovascular coupling is in part mediated by a direct interaction with interneurons [5,21,22] via 
the release of vasoactive messengers. As functional postsynaptic nicotinic acetylcholine receptors (nAchRs) are 
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only expressed by non Fast Spiking (FS) neocortical inhibitory interneurons [23-25], DMPP allows a specific 
neuronal activation.  
Here, we observed that for both direct and indirect stimulation protocols, the amplitudes of evoked blood vessel 
movements were not significantly different in APPxPS1 versus WT mouse. We find that activation of 
neocortical interneurons with DMPP could dilate blood vessels via Nitric Oxide (NO) or constrict blood vessels 
via Neuropepide Y (NPY) release. However, theis neuronal stimulation using DMPP induced less vasomotor 
responses in APPxPS1 compared to WT mice. These findings suggest that a loss of neuronal control rather than 
a purely vascular impairment underlie the neurovascular alteration occurring during the development of AD. 
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Material and Methods 
Animals  
We used nine wild type C57Bl6J (WT) and six APPxPS1 transgenic 8 month-old male mice, as previously 
described [19]. Transgenic mice (Tg) were generated by crossing homozygous PS1 (carrying presenilin 1 
M146L mutation under the control of the HMG-CoA reductase promoter) with hemizygous APPSL mice 
(hAPP751 transgene with the Swedish K670N/M671L and London V717I mutations, under the control of the 
Thy1 promoter) to obtain APPxPS1 transgenics. 
All animals were housed in a temperature-controlled (21–25°C) room under daylight conditions. They arrived in 
the laboratory 2 weeks before initiating experiments to acclimate to their new environment. Experimental 
procedures were conducted in strict compliance with approved institutional protocols and in accordance with the 
provisions for animal care and use described in the European Communities Council directive of 24 November 
1986 (86-16-09/EEC). Experiments were performed in compliance and following approval of the Sanofi-Aventis 
Animal Care and use Committee.  
 
Slice preparation  
Mice were anesthetized using halothane and decapitated. Brains were quickly removed and placed into cold (~4 
°C) cutting solution containing (in mM): 110 choline chloride, 11.6 Na-ascorbate, 7 MgCl2, 2.5 KCl, 1.25 
NaH2PO4, and 0.5 CaCl2, continuously bubbled with 95% O2 – 5% CO2. Coronal brain slices (300 µm thick) 
comprising the somatosensory cortex were cut with a vibratome (VT1200S; Leica, Nussloch, Germany), and 
transferred to a holding chamber filled with artificial cerebrospinal fluid (ACSF), containing (in mM): 126 NaCl, 
2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2, 26 NaHCO3, 20 glucose, and 1 kynurenic acid (a nonspecific 
glutamate receptor antagonist, Sigma, France), constantly oxygenated (95% O2 – 5% CO2) and held at room 
temperature. Individual slices were next placed in a submerged recording chamber kept at 32°C and perfused 
(1.5 ml/min) with oxygenated ACSF (in the absence of kynurenic acid). Blood vessels were visualized in the 
slice using infrared videomicroscopy with Dodt gradient contrast optics.  
  
Drugs  
Thrombaxane A2 receptors and nicotinic acetylcholine receptors agonists (9,11-dideoxy-11a,9a-
epoxymethanoprostaglandin F2α, U46619, 50 nM and 1,1-Dimethyl-4-phenylpiperazinium iodide, DMPP, 100 
µM, respectively, Sigma, France) were added in the ACSF perfusion of the cortical slices for 6 min. To block the 
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NOS, slices were treated for at least 1 h with an irreversible inhibitor of constitutive nitric oxide synthase 
(nNOS) and a reversible inhibitor of inducible nitric oxide synthase (iNOS), Nω-Nitro-L-arginine (L-NNA; 100 
µM; Sigma, France). NPY Y1 receptors were blocked with the selective antagonist N2-(Diphenylacetyl)-N-[(4-
hydroxyphenyl)methyl]-D-arginine amide (BIBP 3226; 100 µM; Sigma, France). 
 
Vascular reactivity  
Blood vessel movements were monitored at 32°C by infrared videomicroscopy on cortical slices. Blood vessels 
remaining in focal plane for more than 50 µm, exhibiting a well-defined luminal diameter (10-20 µm) and 
located in supragranular layers of the somatosensory cortex were selected for vascular reactivity. Images were 
acquired every 15 s using Image Pro Plus 7.0 (MediaCybernetics, San Diego, CA) and control baselines of blood 
vessel diameters were determined for 5 min. Blood vessels with unstable baseline were discarded from the 
analysis. U46619 or DMPP were applied during 6 minutes after stable baseline period. Luminal diameters were 
quantified off-line at different locations along the blood vessel using custom written routines running within 
IgorPro (Wavemetrics) to determine the most reactive part of the vessel. Maximal vasomotor responses were 
then expressed as percentages of the mean baseline diameter during the control period. 
 
Statistical analyses  
To determine the statistical significance of the vasomotor responses, changes in diameter were compared using a 
paired t-test at the time before the onset of the drug application where the mean diameter change is closest to 0% 
and at the time where the maximal response was observed. Vascular reactivities in control WT versus APPxPS1 
mice were compared using t-test. To compare the proportions of reactive blood vessels in WT versus APPxPS1, 
we used a z test. The Area Under the Curve (AUC) for the vascular response of each blood vessel was calculated 
using the trapezoidal rule. For U46619 study, the AUC was calculated as the incremental or decremental values 
from the baseline obtained during the 27 minutes (from time 3 to 30 minutes after U46619 onset application). 
For DMPP study, the AUC was calculated as the incremental or decremental values from the baseline obtained 
during the 12 minutes (from time 0 to 12 minutes after DMPP onset application). Comparisons of AUC among 
genotype groups were performed by Mann Whitney U test. The AUC was expressed in arbitrary units. 
 
Histology and Immumohistochemistry 
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Following the recordings of blood vessel reactivity, slices were fixed over night. Amyloid deposits were labeled 
by standard Congo red staining [26], and amyloid loads were manually delineated and quantified with Photoshop 
CS3. A total of 2-3 measures were performed and averaged for every mouse. Evaluation of amyloid loads was 
performed in the barrel somatosensory cortex and in the CA1 region of the hippocampus. Blood vessels in 
transgenic versus WT mice were assessed by immunostaining for basement membrane protein collagen-IV (goat 
anti-collagen type IV; 1: 400; Chemicon). Blood vessels density was measured using computer-based 
thresholding methods in Photoshop CS3. A total of 2-3 measures were performed and averaged for every mouse 
in the barrel somatosensory cortex. 
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Results 
Amyloid deposition and vascular density in 8 month-old APPxPS1 mice  
In order to examine the vascular reactivity in the somatosensory cortex of 8 months APPxPS1 versus WT mice, 
we first looked at the amyloid depositions and the vascular density in this region of interest. Neuropathological 
analyses revealed in APPxPS1 the presence of numerous extracellular aggregated (Congo red positive) A 
deposits (Fig. 1A-C) whereas none could be observed in WT mice. Interestingly, we observed that A deposits 
in the cortex were more numerous and bigger in deep layers, compared to supragranular layers (Fig. 1A and C). 
Some Congo red positive blood vessels were observed (Fig. 1B), indicating a cerebral amyloid angiopathy at 8 
months in this APPxPS1 mice. We quantified Congo red positive aggregates in the cortex and the CA1 field of 
the hippocampus. Amyloid loads represented 4.53 ± 0.57% of the parenchymal tissue in the somatosensory 
cortex, and 5.41 ± 0.66% in the CA1 region (no significant difference between these regions) (Fig. 1E). 
In the cortex, immunostaining of collagen-IV to label blood vessels revealed no difference in the mean vascular 
density in APPxPS1 (12.67 ± 1.48%) compared to the WT mice (15.15 ± 2.61%) (Fig. 1 D and F).  
 
Direct stimulation of blood vessels using U46619 
To determine if purely vascular dysfunctions or a loss of neural control underlay the neurovascular coupling 
impairment observed in AD, we examined blood vessels reactivity in 8 months APPxPS1 versus WT mice. 
Using infrared videomicroscopy on cortical slice preparations, we first investigated a potential vascular 
dysfunction by using direct pharmacological stimulation of blood vessels. We applied a thromboxane A2 stable 
analogue, the U46619 (50 nM) for 6 minutes on acute WT or APPxPS1 cortical slices. We focused our study on 
penetrating arterioles that are known to be of prime importance in feeding deeply located microvessels and 
neurons [27]. Well defined arterioles of supragranular layers were selected for quantitative analyses. This direct 
vascular stimulation induced strong, significant and reversible vasoconstrictions in both WT (80.82 ± 6.59%, n = 
8; p<0.05) and APPxPS1 mice (80.83 ± 3.79%, n = 10; p<0.001) (Fig. 2, Table 1). The diameter change 
measured either at 14 minutes after the onset of U46619 application, where the maximum of the response was 
reached, or at 30 minutes after the onset of U46619 application, did not differ significantly between APPxPS1 
and WT mice. However, when the response of each arteriole to the U46619 application was expressed as the 
area under the response curve (AUC), the percent AUC for the U46619–induced vasoconstriction was 
significantly highest at 30 minutes in APPxPS1 mice compared to WT mice (325.15 ± 47.31 and 183.94 ± 37.91 
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respectively, P<0.05, Table 1). Finally, the proportion of blood vessels that constrict in response to U46619 in 
APPxPS1 mice (10 out of 18) compared to WT mice (8 out of 14) did not differ significantly (p>0.68, Table 1). 
These results suggest that, at 8 months of age, blood vessels recovery following a direct stimulation is slower but 
reactivity remains functional in these transgenic mice. 
 
Indirect stimulation of blood vessels via neuronal activation using DMPP 
Next, in order to investigate whether neuronal release of vasoactive compounds was altered in APPxPS1 mice, 
we used the nicotinic receptor agonist DMPP (100 µM) to stimulate interneurons. DMPP induced, both in WT or 
APPxPS1 mice, either vasodilatations (105.21 ± 1.21%, n = 12 and 106.08 ± 2.91%, n = 3, respectively), or 
vasoconstrictions (95.52 ± 1.08%, n = 7 and 93.42 ± 4.77%, n = 4, respectively; Table 1, Fig. 3). Here again, no 
significant differences (p>0.56) were observed for the mean vasodilatation or vasoconstriction amplitudes 
between both lines of mice. However, the proportion of blood vessels reactive to DMPP was smaller in 
APPxPS1 (7 out of 20) compared to WT (19 out of 27) mice (p<0.05, z-test). In particular, vasodilation were less 
frequently induced by DMPP in transgenic mice (3 out of 20; 15%) compared to WT mice (12 out of 27; 44%; 
Table 1). Following DMPP stimulation, proportion of vasoconstriction in transgenic mice (7 out of 27; 26%) was 
not significantly different compared to WT mice (4 out of 19, 20%; z-test, P>0.8; Table 1). However, no 
significant difference of AUC for DMPP-induced vasodilation or vasoconstriction were observed in APPxPS1 
mice compared with WT mice (P>0.64, Table 1). 
These results suggest that the impairment of the functional hyperemia observed in AD is primarily due to a 
defect in the neuronal control of blood vessels rather than to a pure vascular dysfunction.  
 
Vasodilations induced by DMPP application are mediated by NO whereas vasoconstrictions are due to 
NPY release 
The stimulation of GABAergic interneurons can induce vasomotricity via the production of vasoactive 
substances [5,21,22]. DMPP depolarizes nicotinic cholinergic receptors (nAChR)-expressing interneurons that 
were shown to be also responsive to serotonergic via the serotonin 5-hydroxytryptamine 3A (5-HT3A) receptor 
[28]. As the pharmacological stimulation of this receptor was recently reported to bi-directionally control 
arterioles diameter by the release of NO to dilate, or NPY to constrict [29], we hypothesized that DMPP induced 
vasomotor changes could also be due to NO or NPY release.  
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Therefore, in order to determine the molecular events underlying vasomotor changes following DMPP 
stimulation, we successively blocked different possible mechanisms. Lowering basal NO levels by treatment 
with the constitutive nNOS inhibitor L-NNA (100 µM) prevent all vasodilations in response to DMPP 
applications. Only vasoconstrictions were recorded (94.65 ± 2.41 of baseline diameter; n = 7/16, P<0.01) (figure 
4A). These results suggest that DMPP-induced vasodilations are mediated by NO release.  
Then, to determine the molecular pathway underlying vasoconstrictions, treatment of DMPP was reproduced in 
the presence of NPY Y1 receptor antagonist (BIBP 3226, 1 µM). Indeed, vasoconstrictions mediated by NPY are 
known to be mediated by smooth muscle NPY Y1 vascular receptor [30]. Under BIBP 3226, constrictions where 
blocked and only dilations (106.24 ± 2.02%; n = 5/13; P<0.01) could be recorded (figure 4B). Amplitudes of 
vasomotor responses under these different conditions were not statistically different from control condition. 
Altogether, these data strongly suggest that pharmacological stimulations of nAchRs-expressing interneurons 
induce vasodilations through NO release, whereas they induce vasoconstriction through NPY release and 
activation of its Y1 receptor.  
 
Discussion 
The alteration of the neurovascular coupling occurring during AD, could result either from a purely vascular 
disorder or from a neurodegenerative process leading to a loss of blood vessels control by neuronal activity. 
Indeed, increasing evidence suggests a causal role for vascular disorder in the development of AD. Vascular risk 
factors including hypertension, diabetes, and hypercholesterolemia increase the risk of incident AD dementia 
[31] and regional cerebral hypoperfusion is one of the earliest pathological features of AD. On the other hand, 
various modes of neurodegeneration can coexist in a same mouse model and lead to reduced blood vessels 
innervation [32]. Previous findings already shown that A accumulates in neurons [33-36], as it was also 
observed at 2 months in this model [37], which might cause a synaptic degeneration [1] and lead to neuronal 
death [38]. Extracellular amyolid- induces significant entorhinal neuronal loss of principal and SOM/NPY 
neurons in these APPxPS1 mice [39]. Moreover, autophagy is induced but impaired in affected neurons in the 
AD brain [40,41], causing autophagic vacuoles to accumulate profusely in dystrophic neuritis. This axonopathy 
disturbs neuronal trafficking [42] and could perturb vasomotor peptidergic release.  
 
Vascular dysfunction  
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In the present study, to determine if purely vascular or neuronal dysfunction were responsible for the decreased 
neurovascular coupling occurring during AD, we used either direct blood vessels stimulation, or neuronal 
activation, while recording vasomotor changes. Here, no differences could be observed in the peak amplitude of 
evoked blood vessels movements between WT and APPxPS1 mice using either type of stimulation. However, 
the AUC for the U46619-induced vasoconstriction was significantly highest in APPxPS1 mice compared to WT 
mice, accordingly to in vivo studies that reported in other models of AD that vasoconstrictions are usually 
exaggerated [43-45]. This suggests reduced vessel elasticity, which could be due to CAA. Indeed, CAA was first 
detected from about 20 weeks of age and developed beyond the age of 40 weeks in this mouse line, with a high 
prevalenceof the A40 isoform forming amyloid deposits in the vascular system [46]. The blood a vessel 
inelasticity could compromise mental function by preventing neural regions from reacting to new activity by 
adapting blood supply [47]. 
 
Neuronal dysfunction  
Here, we observed that following a neuronal stimulation, reactive vessels were less numerous in transgenic mice 
compared to WT mice. Therefore, it is likely that neurodegeneration rather than a purely vascular impairment 
could be responsible for the alteration of neurovascular coupling in AD.  
Indeed, a neuronal loss in the entorhinal cortex [39] and an extensive, selective and early neurodegeneration of 
the dendritic inhibitory interneurons of the hippocampus have been observed in this model. At 6 months of age, a 
diminution of 50-60% of SOM-immunopositive neurons was noted [48], in accordance with the loss of SOM 
and/or NPY neurons frequently reported in AD patients and the linear correlation between SOM and/or NPY 
deficiency and A content which have been reported [48]. As extracellular A deposits are observed in the 
hippocampus and in the neocortex (Fig. 1) and [37], this suggest that a neurodegeneration of cortical 
interneurons could be responsible for the decreased proportion of reactive blood vessels following a neuronal 
stimulation observed in this study.  
Alternatively, Alzheimer's disease is characterized by large losses of nicotinic cholinergic receptors [49,50], that 
could also contribute to the lack of reactivity following DMPP application. 
 
Dual role of nAChR-expressing interneurons 
Our results indicate that activation of nAChR-expressing interneurons induces a complex vascular response. 
Indeed the selective nAChR agonist DMPP induced either constrictions (37%) or dilations (63%) of penetrating 
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arterioles within supragranular layers. All vasoconstrictions were abolished in the presence of the NPY receptor 
antagonist (BIBP 3226), suggesting that they were elicited by NPY release. This result confirm and extend prior 
studies implicating NPY in vasoconstrictions [21,51,52]. 
Conversely, DMPP-induced dilations were blocked in the presence of a nNOS inhibitor suggesting that NO is 
the predominant messenger inducing the vasodilation, in line previous studies performed in the cerebellum 
[22,53,54] and in the cortex [21,55-59]. This result confirm the previous observation that nAChRs activation 
increased levels of the metabolites of NO, and therefore presumably of NO [60]. Together, our observations that 
in the somatosensory cortex a selective nAChR agonist induce NO mediated vasodilations confirms and extends 
prior studies reinforcing the central role of NO in the neurovascular coupling. 
 
Role of astrocytes in the vascular response to DMPP  
Astrocytes are known as cellular intermediaries that couple neuronal activity to local blood flow changes through 
the phospholipase A2 (PLA2)-mediated synthesis of arachidonic acid, which leads to production of 
prostaglandins and epoxyeicosatrienoic acids [61].  
In the present study, we demonstrated that following DMPP stimulation, vasoconstrictions were mediated by 
NPY release. This neuropeptide is released by interneurons and directly activates NPY Y1 receptors located on 
vascular smooth muscle cells. Otherwise, we demonstrated that following DMPPP stimulation, vasodilations 
were mediated by NO release. NO is known to either directly acts on vascular smooth muscle cells through 
cGMP-PKG [62,63] or indirectly interacts with numerous signaling pathways also involved in the vascular 
control [64-66]. In particular, NO could induce astrocytic cytosolic Ca2+ increased [67]. However, in vivo data 
strongly suggest that the involvement of astrocytes is likely to occur in the late phase of the neurovascular 
coupling [68,69]. Even if further experiments would be necessary to fully characterize the NO mediated 
vasodilations following DMPP application, it appears that in our stimulation conditions, no other components 
possibly released by astrocytes are involved in the neurovascular coupling. 
 
Conclusion 
In this study, we observed by infrared videomicroscopy, the cortical vascular response induced by either a 
vascular activator, the thomboxane A2 analogue, or by a neuronal activator, the nicotinic agonist DMPP in an 
APPxPS1 transgenic mouse model of AD. No differences were observed in the amplitude of vascular responses 
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between WT and transgenic mice following both types of activators. Therefore, in this mouse model of AD a 
neuronal alteration rather than vascular changes seems responsible for the impaired neurovascular coupling. 
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Figure Legends 
 
 
Figure 1: Neuropathological profile of 8 month-old APPxPS1 mice. A-C, APPxPS1 develop brain 
amyloidosis as evidenced by numerous Congo red positive plaques in the parenchyma and blood vessels. B and 
C are magnifications of a blood vessel positive for Congo red and a parenchymal amyloid deposit, respectively, 
as outlined in A. D, Immunolabbeling of collagen IV revealed blood vessels architecture within the cortex. E, 
Regional amyloid loads (mean ± sem) were calculated from Congo red sections in different brain region 
(somatosensory cortex and CA1). Note that the relative volume occupied by amyloid loads is not significantly 
different in CA1 versus Cortex of APPxPS1 mice. F, Vascular density (mean ± sem) was calculated from 
collagen IV immunostaining in the somatosensory cortex. 
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Figure 2: Vasoconstrictions induced by direct stimulation of blood vessels using U46619 were not 
significantly different in APPxPS1 compared to WT mice.  
A, Mean vascular constrictions ± sem induced by U46619 (50 nM) in 8 month-old APPxPS1 (n = 10, open 
circles) and WT (n = 8, filled lozenges) mice. B, Infrared images of an intracortical blood vessel that reversibly 
constricted in response to bath application of U46619 (50 nM) in an APPxPS1 mouse. C, At 14 min (T14), 
vasoconstrictions shown in (A) were significant in WT (p<0.05) as in APPxPS1 (p<0.001), compared to values 
at T0. No significant differences were detected at 14 min, or at 30 min, between these two lines of mice (p>0.3). 
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Figure 3: Vasodilatations and vasoconstrictions induced by indirect blood vessels stimulation, via DMPP 
induced interneurons activation, were not significantly different in APPxPS1 compared to WT mice. A, 
Mean vascular dilatations (n = 12) and constrictions (n = 7) ± sem induced by DMPP (100 µM) in 8 month-old 
WT mice. B, Mean vascular dilatations (n = 3) and constrictions (n = 4) ± sem induced by DMPP (100 µM) in 8 
month-old transgenic APPxPS1 mice. C, Mean maximal or minimal responses for vasodilatation and 
vasoconstriction, respectively, were compared to initial values (at T0) for WT and APPxPS1 mice and between 
WT and APPxPS1 mice.  
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Figure 4: DMPP induced vasodilations are mediated by NO while constrictions are mediated by NPY in 8 
month-old WT mice. A, Mean vasoconstriction (n = 7) ± sem induced by DMPP (100 µM) in the presence of 
nNOS inhibitor L-NNA (100 µM). B, Mean vascular dilation (n = 5) ± sem induced by DMPP (100 µM) in the 
presence of the NPY Y1 receptor antagonist BIBP 3226 (1 µM). 
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Table 1 
Vascular reactivity induced by U46619 (50 nM) or DMPP (100 µM) applications in WT and APPxPS1 mice 
cortical slices. Mean vVascular dilation (white line) or constriction (grey lines) are indicated for each condition 
as mean diameter change or mean AUC ± sem. Proportions of reactive of blood vessels following by U46619 
(50 nM) or DMPP (100 µM) applications were determined in WT and APPxPS1 mice cortical slices. 
 
 Diameter change (%) AUC Reactivity (%) 
 WT APPxPS1 WT APPxPS1 WT APPxPS1 
U46619 80.18 ± 4.79 80.83 ± 3.79 183.94 ± 37.91 325.15 ± 47.31 57 56 
DMPP 
105.21 ± 1.21 106.08 ± 2.91 39.40 ± 8.49 39.22 ± 21.23 44 15 
95.52 ± 1.08 94.71 ± 0.88 27.77 ± 9.64 35.86 ± 14.89 26 20 
 
 
 
 
Table 2 
Vascular reactivity induced by DMPP applications in WT mice cortical slices in the presence of L-NNA or BIBP 
3226. Vascular dilation (white line) or constriction (grey lines) are indicated for each condition as mean diameter 
change or mean AUC ± sem. Proportions of reactive of blood vessels following DMPP (100 µM) applications 
were determined in WT mice. 
 
 
 Diameter change (%)        AUC Reactivity (%) 
 WT WT  WT 
DMPP + BIBP 3226 106.24 ± 2.02 39.75 ± 6.21  38 
DMPP + L-NNA 94.65 ± 2.41 26.76 ± 6.00  44 
 
 
 
